Clinical Trial Search

Primary: Time Weighted Average (TWA) Change From Baseline in Pain Score Over 48 Hours Between TRV130 and Placebo — -3.1; -3.1; -2.6; -3.3 score on a scale

Primary: Change From Baseline in the 16-Item Negative Symptom Assessment (NSA-16) Total Score at Week 6 and Week 12 — 61.0; 60.4; -5.0; -3.4 score on a scale — p=0.073

Primary: Dyspnea Numeric Rating Scale — -2.4; -1.1 score on a scale

Primary: Change From Baseline Osteoarthritis (OA) Pain in the Target Knee — -23.3; -23.5; -21.3; -22.1 score on a scale — p=0.575

Primary: SUV Max on PET/CT Scan at 12 Months — 26.1; 22.9 g/ml

Primary: Time Weighted Average (TWA) Change From Baseline in Pain Score Over 24 Hours Between TRV130 and Placebo — -3.8; -1.7; -3.5; -1.2 score on a scale

Primary: Percent Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -25.6; -30.4; -25.9; -6.3 percent — p=0.011

Primary: Objective Response Rate — 2 Participants

Primary: Mean Change From Baseline (Pre-Dose) Twice Daily Averaged Subject-rated Reflective Total Nasal Symptom Score (TNSS) — -1.19; -1.58; -1.68; -1.63 score on a scale

Primary: Mean Change From Baseline (Pre-Dose) in Subject-rated Reflective TNSS — -1.84; -1.71; -1.47; -0.99 score on a scale

Primary: Number of Participants Smoking-Abstinent for 7 Days, 26 Weeks Post Quit Date — 5; 1 Participants

Primary: Mean Change From Baseline in Average Lissamine Green Staining in the Study Eye — -0.65 score on a scale

Primary: Change in Serum Phosphate Levels — -.47; -1.18; -1.7; -1.98 mg/dL — p=0.012

Primary: Percent Change From Baseline in the Rosacea Clinical Score Card — -0.63; -0.00063; -0.65; -0.34 percent change

Primary: Mean Change From Baseline (Pre-Dose) in Subject-rated Instantaneous TNSS — -1.17; -0.69; -2.43; -1.65 units on a scale